The Heart Attack He Did Not Know He Had

The referral note said “pre-operative cardiac clearance, right knee replacement, 61-year-old male, type 2 diabetes x 14 years, no cardiac history.” The resting ECG that the anesthesiologist ordered as part of the routine workup came back with a note from the reading cardiologist: “Q waves in leads II, III, and aVF consistent with prior inferior myocardial infarction.” The patient, when called with this finding, was quiet for a moment, then said: “But I’ve never had a heart attack.” He was right that he had never been told he had a heart attack. He was wrong that he had never had one.

How Common Is This

The question of how often men have myocardial infarctions that are never recognized as such is one that cardiologists answer with a range rather than a precise number, because the answer depends heavily on how you look for the event. Population-based screening studies using serial ECGs in community cohorts have found that somewhere between 20 and 40 percent of myocardial infarctions in men may be silent or unrecognized at the time of the event.

The Framingham Heart Study, which followed a community cohort with periodic ECG surveillance over decades, found that approximately 28 percent of MIs detected during the study were unrecognized by the participant at the time of the event, discovered only on a subsequent ECG showing new Q waves. The prevalence of silent MI increased with age and was substantially higher in men with diabetes than in those without. The MESA (Multi-Ethnic Study of Atherosclerosis) study found similar rates using cardiac MRI, which can detect myocardial scar even when the ECG is non-diagnostic, suggesting the ECG-based estimates may undercount silent events.

The absolute number of silent MIs matters as much as the percentage. Men have higher rates of MI overall than women through age 74, so a 25 to 30 percent silent fraction in a higher-prevalence population translates to a large absolute number of men walking around with unrecognized prior infarction, unmanaged risk, and no secondary prevention in place.

The Attribution Problem: Why “Silent” Is Not Always Accurate

The medical category of “silent MI” contains at least two distinct populations that carry different clinical implications and deserve different framings.

The first population is truly silent: men with severe diabetic autonomic neuropathy who had an infarction during which pain signaling was so impaired that the event genuinely produced no perceptible symptom. The heart muscle was dying. No signal reached conscious awareness. These are the patients who had dinner and watched television during an inferior MI.

The second, and arguably larger, population experienced symptoms that were present but attributed to something else. A man who had crushing mid-sternal heaviness while mowing the lawn that resolved when he stopped and sat for twenty minutes may have attributed this to “overdoing it,” or to heartburn from the chili he had for lunch, or to the fact that he had not been sleeping well. He did not seek care. He did not die. The symptom resolved. Life continued. The ECG done seven years later shows the scar from that lawn-mowing afternoon.

This is the attribution problem, and it is, in important ways, a male-specific phenomenon. The popular culture framing of a heart attack as a man clutching his chest and collapsing has been absorbed by men as the standard against which they compare their own symptoms. A symptom that does not match this dramatic template is classified as something else, and the classification is usually benign. Men are systematically less likely than women to call emergency services for cardiac symptoms that present atypically, and men are more likely to delay hospital presentation when symptoms are present. 4 / Promising The irony is that the condition most associated with the dramatic stereotyped presentation, the anterior STEMI from total LAD occlusion, often does produce dramatic symptoms. It is the inferior and lateral MIs, often from right coronary or circumflex territory, that are more likely to present with symptoms that are milder, atypical, or easily misattributed.

The ECG Discovery: Reading the Scar

Pathological Q waves on a resting ECG are the most common way a prior silent MI surfaces. Understanding what those Q waves mean and where to look for them is essential context for any man receiving this finding.

Myocardial infarction kills myocytes and replaces them with fibrotic scar tissue. Scar does not conduct electrical signals. When a region of the left ventricle is scarred, the electrical vector from that wall is absent, and the ECG, which records the net electrical vector of all walls simultaneously, develops a characteristic absence: instead of moving toward the infarcted wall (which would produce a positive deflection), the early QRS complex vector moves away from it, producing the negative Q wave that is the electrocardiographic signature of transmural infarction.

The territory of the Q waves tells the treating cardiologist which artery was involved. Inferior Q waves in leads II, III, and aVF indicate prior infarction in the inferior wall of the left ventricle, the territory supplied by the right coronary artery in most individuals. Anterior Q waves in leads V1 through V4 indicate prior infarction in the anterior wall and septum, the territory of the left anterior descending artery. Lateral Q waves in leads V5 through V6, with or without changes in leads I and aVL, indicate prior infarction in the lateral wall, the territory of the circumflex artery or its diagonal branches.

The size of the Q wave matters. A Q wave must be at least 40 milliseconds in duration (one small box on the ECG at standard speed) and at least 25 percent of the following R wave amplitude to qualify as pathological by most criteria. Isolated small Q waves, particularly in leads III and aVL, can be positional rather than ischemic and require clinical context.

Diabetes as the Dominant Driver

The single strongest predictor of silent MI in men, more than age, more than the degree of coronary disease burden, is the presence of diabetes. The mechanism is autonomic neuropathy, and the pathway is specific.

Diabetic autonomic neuropathy affects the small, unmyelinated nerve fibers that carry visceral pain signals, including those from the cardiac afferent nerves. These are the same fibers that, when functioning normally, transmit the signal of myocardial ischemia to consciousness: the crushing chest pressure, the arm radiation, the diaphoresis, the nausea that are the classical features of a recognized MI. When those fibers are damaged by sustained hyperglycemia and the downstream glycation, oxidative stress, and microvascular injury that hyperglycemia produces, the cardiac pain signal is either absent or substantially attenuated.

The same peripheral neuropathy that makes a man lose protective sensation in his feet, so that a foot ulcer develops without his awareness, is affecting the afferent nerves from his heart. The mechanism is the same. The clinical consequence in the foot is the diabetic foot wound. The clinical consequence in the heart is the silent MI.

Long-standing diabetes, defined roughly as more than ten years of disease duration, carries substantially higher risk than newly diagnosed diabetes. This is because autonomic neuropathy is a complication that develops over time, with cumulative glycemic exposure the primary driver. However, the relationship between HbA1c control and autonomic neuropathy risk is imperfect: some men with well-controlled diabetes still develop neuropathy, and glycemic control reduces but does not eliminate the risk. 4 / Promising

The practical implication for any man with type 2 diabetes is that the absence of anginal symptoms does not indicate the absence of cardiac ischemia. It indicates that the pain-reporting mechanism may be unreliable. The cardiologist’s job in this population is not to be reassured by the absence of symptoms. It is to assess the coronary anatomy and function through methods that do not depend on symptom reporting.

The Wall-Motion Discovery: When the Echo Asks the Question

Many silent MIs surface not on ECG but on echocardiogram, the ultrasound imaging of the heart that is ordered for a wide variety of reasons including shortness of breath, hypertension evaluation, murmur assessment, or pre-operative risk stratification. The echocardiogram shows the mechanical consequence of the prior infarction: a region of the left ventricle that moves poorly or not at all, the echocardiographic correlate of the scarred territory.

Regional wall-motion abnormalities (RWMAs) in the absence of any prior cardiac history are one of the most clinically significant “incidental” findings in cardiology. When the echocardiographer reports hypokinesis of the inferior wall, or akinesis of the anterior apex, in a man who has never been told he has had a heart attack, the finding is not a minor incidental. It is the discovery of a prior infarction that was never diagnosed and never treated.

The echocardiographic finding of a RWMA triggers a clinical cascade that should be similar to the cascade triggered by a recognized MI: risk factor assessment, medication review, and likely coronary angiography or functional stress testing to assess the remaining viable myocardium. The fact that the event was not recognized at the time does not reduce its clinical significance. What it does is impose a secondary prevention gap: the man who had the inferior wall MI in 2019 and is discovered in 2026 has had seven years without the medications and risk factor management that the event should have established.

High-Sensitivity Troponin and the Incidental Finding

High-sensitivity cardiac troponin assays, which became standard in many health systems over the past decade, are substantially more sensitive for myocardial injury than prior generation assays. This sensitivity has generated a clinical phenomenon that did not exist before: incidentally elevated troponin discovered in blood drawn for reasons unrelated to cardiac symptoms.

A man sent for pre-operative laboratory work before a hip replacement, or whose life insurance application included a full metabolic panel with high-sensitivity troponin, may receive a call informing him that his troponin is elevated. The distinction between an elevated troponin representing acute myocardial injury (requiring emergency evaluation) and an elevated troponin representing chronic, low-level myocardial injury from prior infarction, cardiomyopathy, or chronic ischemia requires serial measurement and clinical context.

A single elevated high-sensitivity troponin in an asymptomatic man is not a diagnosis. It is a finding that requires a follow-up measurement at two to three hours to distinguish a rising pattern, which suggests acute injury, from a stable elevation, which is more consistent with chronic injury or non-ischemic myocardial disease. The stable elevated troponin in an asymptomatic man should prompt cardiac evaluation, including ECG, echocardiogram, and clinical history, but it does not require the same emergency response as an acutely rising troponin in a patient with chest pain. For the full clinical interpretation of troponin elevation in men, including sex-specific reference ranges and how to distinguish acute from chronic elevation, see the dedicated guide.

Coronary Artery Calcium and the Pre-Event Window

Some men discover their cardiovascular risk not through a silent MI finding but through a coronary artery calcium (CAC) score obtained as part of cardiovascular risk screening, a preventive health assessment, or incidentally on a CT of the chest done for another reason. A CAC score of 400 or above in a man at age 52, discovered incidentally, is clinically significant. It indicates a substantial atherosclerotic plaque burden and a meaningful probability of obstructive coronary disease, even in the absence of symptoms.

The man with a CAC score of 400 who has had no prior cardiac evaluation does not know whether he has already had a subclinical MI or whether his coronary disease burden is pre-event. The CAC score itself does not distinguish between these possibilities, but it establishes that he is at high risk for both a first event and for having already had an unrecognized one. The appropriate next step, after the CAC finding, is a clinical evaluation that includes ECG, echocardiogram, and a careful symptom history over the prior five to ten years.

The Secondary Prevention Gap

The clinical problem at the center of the silent MI story is not primarily diagnostic. It is preventive. A man who has a recognized MI is enrolled in secondary prevention: the drug and lifestyle framework that substantially reduces the risk of a subsequent event and limits the cardiac remodeling that follows myocardial necrosis. He is likely started on a high-intensity statin to stabilize remaining plaque and slow further atherosclerotic progression. He receives antiplatelet therapy to reduce thrombotic event risk. Cardiac rehabilitation improves his exercise capacity, autonomic function, and psychosocial outcomes.

The man who had the same MI but never recognized it gets none of this, for the duration of the diagnostic gap. If his silent MI occurred in 2019 and was discovered in 2026, he had seven years during which his coronary plaque continued to develop, his blood pressure was managed (or not) without knowledge of the cardiac event, and his next MI, if it occurs, will occur without the secondary prevention foundation that the first event should have established.

The cardiovascular risk of a prior MI, recognized or not, is substantial and ongoing. The myocardial scar creates a substrate for ventricular arrhythmias at the junction between scar and viable tissue. The loss of contractile myocardium, if the territory was large, produces chronic mechanical disadvantage. The coronary disease that caused the first MI is still present and still progressing. None of these biological realities care whether the patient received a diagnosis or not.

Who Should Be Evaluated

The clinical population that warrants specific evaluation for prior silent MI is not difficult to identify. Men with type 2 diabetes over the age of 45, particularly those with disease duration exceeding ten years, should have a baseline resting ECG to look for Q waves indicating prior infarction. When the ECG is abnormal or equivocal, echocardiography to assess for regional wall-motion abnormalities is the appropriate next step. Men with diabetes who have any unexplained reduction in exercise tolerance, any fatigue that is out of proportion to their overall health status, or any symptom that in retrospect could represent an atypical ischemic equivalent, deserve a lower threshold for functional cardiac evaluation.

Beyond the diabetes population, men over 50 with multiple cardiovascular risk factors, particularly those with a high CAC score discovered incidentally, should have ECG evaluation as part of their baseline cardiovascular risk assessment. Men with new incidentally elevated high-sensitivity troponin require serial measurement and clinical evaluation regardless of symptom status.

The ECG is an inexpensive, widely available test. The echocardiogram is more expensive but is non-invasive and widely accessible. The clinical yield of these tests in the high-risk population defined above is substantially higher than in the general population, and the clinical consequence of a missed prior MI is serious enough to make the evaluation worthwhile.

The man who had the right knee pre-operative ECG ended up in the catheterization laboratory the following week. His right coronary artery had a 70 percent stenosis at the site of the prior infarction. He was enrolled in secondary prevention the same day. He asked whether the knee replacement would still go forward. It did, now with the appropriate cardiac improvement in place. He had spent seven years without it.

For the diabetes-heart disease connection: Diabetes and Heart Disease.

For understanding coronary artery calcium scoring: Coronary Artery Calcium Score.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.